OR WAIT null SECS
VANCOUVER -- Response Biomedical Corp. announced the company's RAMP(R) Anthrax Test is the only rapid biological detection system to meet the new performance standards introduced by AOAC INTERNATIONAL for rapid immunoassay-based anthrax detection systems. Following rigorous independent evaluation, funded by the U.S. Department of Homeland Security (DHS), the RAMP Anthrax Test is now laboratory-tested and approved as both an AOAC Performance Tested Methods(SM) (PTM) and Official Methods of Analysis(SM) (OMA).
"AOAC INTERNATIONAL uses a time-tested and exceptionally rigorous process in evaluating analytical methodology. The RAMP system performed well in this rigorous evaluation, and that says quite a lot about it. AOAC and DHS are working rapidly to ensure that the RAMP System will be a very useful tool for first responders," stated E. James Bradford, PhD, executive director, AOAC INTERNATIONAL.
"We applaud DHS for commissioning a definitive evaluation and facilitating the introduction of prescribed performance standards to enable first responders to make informed purchasing decisions," states Bill Radvak, president and CEO, Response Biomedical Corp. "The broad publication of these results which unequivocally demonstrate RAMP's market-leading performance will ensure that emergency responders and corporate America have immediate access to the very best technology available, providing enhanced protection and peace of mind to millions of Americans, public safety personnel and corporations."
Source: Response Biomedical Corp.